All In Biotech

Drug Trial Radar · NCT04947137

Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

Last checked: Nov 20, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

134

Actual

Start

May 27, 2021

Primary completion

Jan 21, 2022

Study completion Jan 21, 2022

Sponsor

Lead sponsor
Navidea BiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Tc99m tilmanoceptDrug

    Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Normal Limits of TUVjoint in Healthy SubjectsTime frame: Up to 39 days
  2. Qualitative Evaluation of SPECT/CT for Tilmanocept LocalizationTime frame: Up to 39 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • San Marcus Research Clinic

    Miami Lakes, Florida

  • Innovation Medical Research Center

    Palmetto Bay, Florida

  • Kettering Medical Center

    Kettering, Ohio

  • Essential Medical Research

    Tulsa, Oklahoma

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Sun Research Institute

    San Antonio, Texas

  • Tranquility Research

    Webster, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.